| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 21, 2025 |
| By Fraiser Kansteiner The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.S. The update will likely put pressure on compounding pharmacies, which have raked in major revenues marketing knockoff versions of Novo's drug during the shortage. |
|
|
|
By Gabrielle Masson The Trump administration is exploiting an administrative loophole to keep federal research funding frozen, despite a federal judge ordering for a halt to the action, according to Nature. |
By Conor Hale Roche said its technique combines aspects of DNA synthesis and nanopore-based reading to provide a clear signal in the molecular noise. |
By Fraiser Kansteiner A little less than two years after San Francisco’s Mirum Pharmaceuticals ponied up $210 million to acquire Travere Therapeutics’ bile acid portfolio, the deal has paid off with a fresh FDA approval. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Darren Incorvaia Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene therapy, data that is prompting the biotech to seek accelerated approval in AIPL1-associated severe retinal dystrophy. |
By Andrea Park A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal stereotypes and misconceptions about the condition. |
By Darren Incorvaia A slimmed-down BioMarin started the new year open for business, seeking to leverage its unique skillset to strike deals that bolster its pipeline of medicines for genetic diseases. |
By Angus Liu Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez. The move leaves no active gene therapy programs in Pfizer's portfolio. |
By Kevin Dunleavy Less than a week after newly confirmed HHS secretary Robert F. Kennedy Jr. questioned the integrity of experts on the Centers for Disease Control and Prevention vaccine advisory committee, the agency has postponed the group’s meeting next week. The ACIP was set to meet in Atlanta Feb. 26-28 and weigh in on new and updated vaccines. |
By Darren Incorvaia,Zoey Becker The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies. |
By Kevin Dunleavy Private equity firms Carlyle and SK Capital have agreed to pay $29 million to acquire bluebird bio, which has struggled to commercialize three gene therapy products. |
By Andrea Park,James Waldron,Gabrielle Masson This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
By Nick Paul Taylor The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now.
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
